corporate presentation 2017  Symbol: BSGM 

 Disclaimer  Symbol:BSGM  *  This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig’s products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig’s control. These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig’s products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig’s ability to effectively react to other risks and uncertainties described from time to time in BioSig’s SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility. BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.  

 Symbol:BSGM  *  Visibility Leads to Cures  In 1900, a third of all US deaths were from pneumonia, tuberculosis and diphtheria  In 2014, less than 1000 people died from these diseases  Today heart problems are the number one cause of death  Better visualization enabled these successes  BioSig is developing technologies to help doctors better visualize abnormal heart rhythms  There may be a multi-billion dollar potential market for our patent-pending medical visualization technology 

 Risk of stroke 4-to 5-fold(5th leading cause of death in US)  Symbol:BSGM  *  Atrial Fibrillation (AFib)Background  Normal Heart Rhythm  Atrial Fibrillation (as one example of acomplex arrhythmia)  Everyone over 40 has a 1 in 4 lifetime risk   Affects > 6M in US  Rapid/irregular heart rate  Complex arrhythmias expensive due to multiple ablation procedures needed  Sources: CDC, http://www.preventaf-strokecrisis.org/files/files/The%20AF%20Report%2014%20April%202012.pdf  Left Atrium  Right Atrium  SA Node 

 Improved signals should enable more precise treatment and less procedures  Ventricular Tachycardia (VT)  Symbol:BSGM  *  Normal Heart Rhythm  VentricularTachycardia  ≈ 450,000 Sudden cardiac deaths in the US annually  Rapid / irregular heartbeat in the ventricles of the heart  Rapidly fatal if not reversed  Can be treated with ablation  Left Ventricle  SA Node  Right Ventricle 

 Current Diagnosis to Treatment  Symbol:BSGM  *  ECG  Medication  EP Study  Ablation  Diagnose  ChooseTreatment  BioSig’s Focus: Improve Diagnosis Increase Ablation Success 

 Goal: Improve cardiac signal accuracy to reduce costs; repeat procedures  Symbol:BSGM  *  Ablation: One Current SolutionFor Atrial Fibrillation (AFib)  Catheter inserted into heart  Scars tissue that harbors abnormal heart rhythm  Left Atrium  Catheter  (1)http://journals.lww.com/ajnonline/Fulltext/2015/10000/CE___Catheter_Ablation_of_Atrial_Fibrillation.25.aspx  The catheter will use either heat or cold to scar the tissue  When done in the right place AFib stops 

 Comparison with Competition  Symbol:BSGM  *  Micro-componentsrevealed  Competition in Blue  BioSig’s PURE EP™ System in Red  Noisy Signal  Noisy Signal  Low amplitude signals revealed 

 Driver: Ablation becoming first line of therapy   Large & Fast Growing Market  Symbol:BSGM  *  EP Labs: Estimated 5,000 WW; 3,000 in the USBy 2020, expected 422,000 procedures in the US with over $3B in revenues    EP Devices  Current EP Market is <$4 B worldwide  $ in Billions  Procedure Growth  Procedures 

 Competitive Landscape EP Recording Devices  Symbol:BSGM  *  ~$1 BILLION Installed Base   Our competitors’ technology is dated 

 Symbol:BSGM  *  PURE EP System Testimonial  "The dynamic range of the system is larger - likely will translate into better ability to see both large and small (frequency and amplitude) signals with similar resolution. This is a major problem with present systems, where in order to see smaller signals, we have to amplify the signals, and in doing so, we lose the ability to see larger signals without saturating these signals.”  “The improved resolution may translate to better ability to pick up specific signals and relate them to specific structure and substrate.”  "The display options are also more intuitive and flexible.  For example, different filtering can be applied to the same signal and displayed as separate, simultaneous signals.  Presently this is not possible with the existing systems to my knowledge."  Samuel J. Asirvatham, M.D. Mayo Clinic  MDDI - http://www.mddionline.com/article/cutting-out-noise-target-arrhythmias-07-08-15 

 Path To Market  Symbol:BSGM  *  2017  2017  2017  2017  2018  Q1  Q2  Q3  Q4  Q1            FDA Review   Launch Prep & Production Builds  MARKET INTRO  Targeted Launch Ver. 1.0   AF SYMPOSIUM  HRS Meeting  Submit Abstracts  510 (k) Clearance  Phase 3Design Refinements Verification Test and Iteration   Phase 2Detailed DesignEngineering Confidence Testing & Beta Build  On going market develop-mentand clinical research 

 Upcoming Major Company Milestones  Symbol:BSGM  *  CATEGORY  Q1  Q2  Q3  Q4  PEER REVIEWED PUBLICATIONS          ON-GOING CLINICAL TRIALS          INDUSTRY SYMPOSIA          NEW PATENT APPLICATIONS          FDA 510(k) CLEARANCE          UPLIST TO NASDAQ          Engineering Journal – 1H 2017Cardiology Journal – 1H 2017  Mayo – Advanced Research InitiativeMount Sinai – VT Scar Model UCLA – Advanced VT Mapping   Heart Rhythm Society – May 10-13, 2017  EHRA-CARDIOSTIM – June 18-21, 2017  Submission 1H 2017  Uplist to NASDAQ  Visualization Tools  Recording EP Procedures  FDA Clearance 2H 2017 

 Symbol:BSGM  *  Board of Directors  Kenneth L. Londoner, MBA  Founder, Executive Chairman, Director; Endicott Management Partners, J & W Seligman & Co  Gregory D. Cash  President, CEO and Director: U.S. Surgical, Boston Scientific, Medtronic  Roy T. Tanaka  Director; Former CEO of BioSense Webster, Johnson & Johnson; Volcano Corp, VytronUS, Coherex Medical  Seth H. Z. Fischer  Director; Current CEO & Dir: Vivus, Inc; Former WW Chairman: Johnson & Johnson, Cardiovascular  Patrick J. Gallagher, MBA  Director; Managing Director Laidlaw & Co.; Kinex Pharma; Founder BDR Research Group, Kidder Peabody  Jeffrey F. O’Donnell, Sr.  Director; CEO, Chair: Trice Medical; Chair: Mela Sciences; Founder: Embrella Cardiovascular  Jerome B. Zeldis, MD, PhD  Director; CEO of Celgene Global Health & Chief Medical Officer of Celgene Corporation; Chairman: Alliqua  David Weild IV, MBA  Director; Founder & CEO: Weild & Co.; Vice Chairman: NASDAQ; Head of Corporate Finance Prudential  Donald E. Foley  Director; CEO & Chair: Wilmington Trust; Sr VP, Treas, & Dir: ITT Corp; Asst Treas: Int’l Paper Co. 

 Proven Management Team  Symbol:BSGM  *  Kenneth L. Londoner, MBA  Founder, Executive Chairman, Director; Endicott Management Partners, LLC, J & W Seligman & Co  Gregory D. Cash  President, CEO and Director; Pres: Argent International, NeuroTherm, Heartsine Tech, Vasomedical, Datascope, Eminent Tech; Mgmt: U.S. Surgical, Boston Scientific, Medtronic  Steve Chaussy, CPA  CFO; Liberski Inc, Anna & Co, Penske Automotive, Ford Hogg and Cobbe  Jay O. Millerhagen, MS, MBA  VP Clinical Research; VP Clinical/Mkt Dev: RESPICARDIA, Inc.; VP/Sr Dir Clinical: St Jude Medical; Dir New Product Planning, Brady Mktg, Heart Failure R&D/Mktg, Bus Alliance Mktg with J&J, GE Healthcare: Boston Scientific  Brian McLaughlin  VP Corporate Finance, Investor Relations; President & COO: Ridgeback Capital; Head of Equity Trading: Sigma Capital; Trader: SAC Capital & JP Morgan & Co. 

 Symbol:BSGM  *  World-Class Scientific Advisory Board   Andrea Natale, MD, Chairman  Executive Medical Director, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center  Samuel Asirvatham, MD  Professor of Medicine & Vice Chair of Division of Cardiovascular Diseases, Department of Medicine; program director Clinical Cardiac Electrophysiology Training Program, Mayo Clinic in Rochester, Minnesota  K. L. Venkatachalam, MD  Assistant Professor of Medicine, Division of Cardiovascular Diseases, Mayo Clinic in Jacksonville, Florida  Kalyanam Shivkumar, MD, PhD  Director, UCLA Cardiac Arrhythmia Center; Professor of Medicine & Radiology  Mauricio Arruda, MD  Director, Clinical Electrophysiology & Pacing, University Hospitals Case Medical Center  Vivek Reddy, MD  Director, Cardiac Arrhythmia Service and a Helmsley Trust Professor of Medicine, Mount Sinai Medical Center in New York  Luigi Di Biase, MD, PhD  Senior Researcher at Texas Cardiac Arrhythmia Institute; Associate Professor, Albert Einstein College of Medicine, Adjunct Professor at the UT Austin 

 Presentations and Manuscripts from Pre-Clinical Studies  Symbol:BSGM  *  Enhanced Electrophysiology Recording Improves Signal Acquisition and Differentiation Presented by team from Mayo Clinic at the 13th Annual International Dead Sea Symposium (IDSS) in Tel-Aviv and available online, March 2016 – Peer ReviewedEnhanced Electrophysiology Recording System Presented at 38th Annual International Conference EMBC 2016, August 2016 – Peer ReviewedNovel electrophysiology signal recording system enables specific visualization of the Purkinje network and other high frequency signals JACC Clinical Electrophysiology, Volume 2, Issue 7, Page 850, December 2016 – Peer Reviewed 

 PURE EP – Development Path Collaborating with Leading Centers  Symbol:BSGM  *  June 2011  Concept Developed with Texas Cardiac Arrhythmia Institute  June 2013  PURE EP System Proof of Concept (POC) Test at UCLA  September 2014  PURE EP System Prototype Test at UCLA  December 2014  Visit to Mayo Clinic to plan Pre-Clinical Studies  March, June &November 2015  Pre-Clinical Studies at Mayo Clinic  July 2016  Commencement of Advanced Research Program at Mayo Clinic   Other Collaborations  Brigham And Women’s Hospital in Boston  June 2016  Initial Pre-Clinical Study at Mount Sinai in NY  UH Case Medical Center in Cleveland 

 EP Sector M&A Activity  *  Company  Proof of Concept  Prototype  Clinical Data  CE Mark  FDA  Sales  Acquirer/Investor  Valuation  HeartWare  •  •  •  •  •  •  Medtronic  $1.1 BillionJune 2016  St. Jude Medical  •  •  •  •  •  •  Abbott  $25 billionApril 2016  Hansen Medical  •  •  •  •  •  •  Auris Surgical Robotics  $80 millionApril 2016  Kalila MedicalFormed 2010  •  •  •  •  •  •  Abbott  UndisclosedFeb 2016  nContactFormed 2005  •  •  •  •      Atricure   $149 millionOct 2015  CardioInsight Formed 2006  •  •  •  •  •  •  Medtronic  $272 millionJune 2015  Topera MedicalFormed 2010  •  •  •  •  •    Abbott  $350 millionDec 2014  Endosense SAFormed 2003  •  •  •  •    •  St. Jude  $331 millionAug 2013  Bard EPDivision of CR Bard  •  •  •  •  •  •  Boston Scientific  $275 millionNov 2013  Rhythmia MedicalFormed 2004   •  •  •            Boston Scientific  $410 millionOct 2012 

 Symbol:BSGM  *  BioSig Technologies, Inc. (BSGM)  OTCQB: BSGMWWW.BIOSIGTECH.COM  Key Company Data  (2/17/17)   Recent price:  $1.54  52-week range:  $1.05 - $2.20  Primary shares i/o:  23.68 million  Float:  11.8 million  Market cap:  $36.47 million  Headquarters:   Minneapolis, MN 

 BioSig Investment Highlights  Symbol:BSGM  *  Large & Growing Cardiac Arrhythmia Patient Population ⇒Ablations Increasing 10%+ Annually $4B Total Addressable Market for EP Devices at 10% Growth Annually ⇒ High Demand for New Technologies World-Class Management Team, Board of Directors & Scientific Advisory Board Aggressive M&A Activity ⇒ High Growth SectorPlan to Uplist to NASDAQ in 2017FDA Submission 1H 2017 ⇒ FDA Clearance 2H 2017 

 Contact BioSig   Symbol:BSGM  *  Ken LondonerFounder, Executive Chairman(203) 644-5200 klondoner@biosigtech.comGregory CashPresident & Chief Executive Officer(612) 309-4747gcash@biosigtech.comBrian McLaughlinVP, Corporate Finance & Investor Relations(917) 370-9817 bmclaughlin@biosigtech.com  This document is being provided on a confidential basis by BioSig Technologies, Inc. solely for the information of those persons to whom it is transmitted. No person in any jurisdiction may treat this document as constituting either an offer to sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely solely on the terms of and disclosure of information including important information regarding risks and conflicts of interest contained in the Company's final offering memorandum and related documents, the only basis on which subscriptions may be made.